Concord Biotech vs Unichem Laboratories vs Aarti Drugs: Which Stock Should You Track

Concord Biotech vs Unichem Laboratories vs Aarti Drugs starts with the core numbers most investors compare within the Pharma CDMO/API (Sixth Fresh Set) segment: market capitalisation, valuation multiples, profitability and dividend yield. Figures below are sourced as of September 2026 and will shift with daily price moves.

All three names sit in the Pharma CDMO/API (Sixth Fresh Set) bucket, which makes them a natural set to place side by side rather than a random trio of unrelated businesses.

Click Here – Get Free Investment Predictions

Concord Biotech, Unichem Laboratories and Aarti Drugs: Company Overview

Concord Biotech is a listed Indian company in the Pharma CDMO/API (Sixth Fresh Set) space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Unichem Laboratories is a listed Indian company in the Pharma CDMO/API (Sixth Fresh Set) space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Aarti Drugs is a listed Indian company in the Pharma CDMO/API (Sixth Fresh Set) space, tracked here on book value, return ratios and valuation alongside its peers in this comparison.

Concord Biotech vs Unichem Laboratories vs Aarti Drugs: Valuation and Profitability Snapshot

Metric	Concord Biotech	Unichem Laboratories	Aarti Drugs
Market Cap (approx.)	Rs 15,453 crore	Rs 3,900 crore	Rs 3,994 crore
PE Ratio (TTM)	56.64	12.80	20.90
PB Ratio	7.66	1.44	2.58
Return on Equity (ROE)	12.94%	2.88%	12.58%
EPS (TTM, Rs)	26.08	43.29	20.94
Dividend Yield	0.51%	0.00%	0.46%
Debt to Equity	0.00	0.18	0.37
Book Value per Share (Rs)	192.81	385.97	169.70

Check the Univest Screener for Live Data

On valuation, Concord Biotech trades at a PE of 56.64 and a PB of 7.66, Unichem Laboratories at a PE of 12.80 and a PB of 1.44, while Aarti Drugs trades at a PE of 20.90 and a PB of 2.58. On return on equity, the three post 12.94%, 2.88% and 12.58% respectively, and on dividend yield they stand at 0.51%, 0.00% and 0.46%.

Concord Biotech vs Unichem Laboratories vs Aarti Drugs: Latest Quarterly Results

Company	Latest Quarter Revenue	Latest Quarter Net Profit	YoY Change (Revenue)	QoQ Change (Revenue)
Concord Biotech	Rs 270.32 crore	Rs 57.70 crore	+24.2%	-20.8%
Unichem Laboratories	Rs 648.23 crore	Rs 41.47 crore	+21.5%	+8.3%
Aarti Drugs	Rs 703.59 crore	Rs 50.13 crore	+19.1%	-2.4%

Quarterly figures above are the most recent reported quarter for each company (Q1 FY28, quarter ended June 2026), compared with the year-ago and preceding quarter.

Download the Univest iOS App or Univest Android App to track Concord Biotech, Unichem Laboratories and Aarti Drugs live prices.

What Should Investors Look at Beyond These Numbers?

Beyond the metrics above, investors comparing these three pharma cdmo/api (sixth fresh set) names should track quarter-on-quarter revenue and margin trends, management commentary on demand and cost drivers, and any sector-specific regulatory developments, since a single-quarter snapshot can shift quickly.

Conclusion

Concord Biotech vs Unichem Laboratories vs Aarti Drugs highlights how differently three companies in the same pharma cdmo/api (sixth fresh set) segment can score across valuation, profitability and dividend metrics, even when operating in a similar space. This comparison does not declare a winner; investors should weigh these figures against their own research and risk appetite. Please read the disclaimer below before making any investment decision.

FAQs on Concord Biotech vs Unichem Laboratories vs Aarti Drugs

What is the market cap difference between Concord Biotech, Unichem Laboratories and Aarti Drugs?

Ans. As of September 2026, Concord Biotech has a market cap of approximately Rs 15,453 crore, Unichem Laboratories is at approximately Rs 3,900 crore, and Aarti Drugs is at approximately Rs 3,994 crore.

Which of the three has the highest PE ratio?

Ans. Among Concord Biotech, Unichem Laboratories and Aarti Drugs, the PE ratios stand at 56.64, 12.80 and 20.90 respectively as of September 2026.

Which of the three has the highest ROE?

Ans. Concord Biotech, Unichem Laboratories and Aarti Drugs post ROE of 12.94%, 2.88% and 12.58% respectively as of September 2026.

Which of these three stocks pays the highest dividend yield?

Ans. Concord Biotech, Unichem Laboratories and Aarti Drugs carry dividend yields of 0.51%, 0.00% and 0.46% respectively.

What is the debt to equity ratio for Concord Biotech, Unichem Laboratories and Aarti Drugs?

Ans. Concord Biotech carries a debt to equity of 0.00, Unichem Laboratories of 0.18, and Aarti Drugs of 0.37.

Which of the three trades at the highest price to book value?

Ans. Concord Biotech, Unichem Laboratories and Aarti Drugs trade at price to book ratios of 7.66, 1.44 and 2.58 respectively.

Is one of Concord Biotech, Unichem Laboratories or Aarti Drugs better than the others?

Ans. This comparison does not declare one stock better than another; each company scores differently across valuation, profitability and dividend metrics, and the right fit depends on an individual investor's own criteria and research.